Objective To observe the efficacy and safety of an intravitreal injection of Ranibizumab combined with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD). Methods Retrospective case series study. To analyze the clinical data of 32 patients (41eyes) with exudative AMD who received an intravitreal injection of Ranibizumab combined with PDT for the initial treatment. All patients were assessed by ETDRS visual acuity chart, color fundus photography, fluorescein angiography (FFA) or indocyanine green angiography (ICGA) and optical coherence tomography (OCT). Patients underwent PDT (600 mW/cm2, 50 J/cm2, 83 s), then Ranibizumab 0.5 mg (0.05 ml) was injected intravitreally 48-72 hours later. Treatments were repeated as follows: a single intravitreal injection of Ranibizumab 0.5 mg (0.05 ml), intravitreal injection of Ranibizumab combined with PDT, or just PDT if the monthly follow-up indicated. Performance on the ETDRS chart and retinal thickness before and after the treatment were analyzed with paired t test, leakage of choroidal neovascularization (CNV) complications were counted, and described by percentages. Results The follow-up period lasted 12-39 months. At the 12th month of the follow-up period, performance on the ETDRS chart had improved by 9.1 letters (t=-4.14, P＜0.01).Intravitreal injections of Ranibizumab were repeated (2.0±1.1)times/eye on average, and PDT was repeated (0.2±0.8)times/eye on average. At the end of the follow-up period, performance on the ETDRS chart had improved by 8.9 letters (t=-3.74, P＜0.01 ). Intravitreal injections of Ranibizumab were repeated (2.7±1.2)times/eye on average, and PDT was repeated (0.3±0.7)times/eye on average.CNV showed complete closure in 9 eyes (22%), partial closure in 27 eyes (66%), no change or expansion in 3 eyes (7%), and new CNV in 2 eyes (5%). The mean foveal thickness in the OCT images decreased 119.11 μm compared to that before treatment (t=4.419, P＜0.01). There was no increase in adverse reactions compared to a single intravitreal injection of Ranibizumab or PDT.Conclusion Intravitreal injection of Ranibizumab combined with photodynamic therapy for exudative AMD is well tolerated, with improvements in visual acuity, FFA or ICGA and OCT performance,and has good efficacy and safety.